Reuters logo
3 个月前
BRIEF-Janssen Pharmaceuticals says evidence shows oral invokana 300 mg demonstrates comparable A1C reduction
2017年5月5日 / 晚上11点13分 / 3 个月前

BRIEF-Janssen Pharmaceuticals says evidence shows oral invokana 300 mg demonstrates comparable A1C reduction

1 分钟阅读

May 5 (Reuters) - Johnson & Johnson

* Janssen Pharmaceuticals - real-world evidence shows oral invokana 300 mg demonstrates comparable A1C reduction and control to injectable GLP-1 receptor agonists

* Janssen Pharmaceuticals Inc - patients on invokana were also less likely to discontinue their medication or be prescribed new antihyperglycemic agent Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below